Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week
Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 SAN JOSE, CA, UNITED STATES, January 19, 2026 /EINPresswire.com/ -- — Biomed Industries, Inc., a …